Search

Copyright of Shandong Medical Journal is the property of Shandong Medical Health Newspapers and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

目的 观察 hnRNP A2/B1蛋白在结直肠癌组织中的表达变化，并分析其与患者预后的关系。方法 采 用免疫组化法和 Western blotting 法检测在 212 例原发性结直肠癌组织和 58 例癌旁正常组织中的 hnRNP A2/B1 蛋 白。根据免疫组化积分的近中位值将结直肠癌标本分为高表达组（积分≥100分）和低表达组（积分<100分）。分析 hnRNP A2/B1蛋白表达与患者临床病理参数及预后的相关性。结果 结直肠癌组织中 hnRNP A2/B1蛋白表达高 于癌旁正常组织（P<0. 01）。Ⅲ、Ⅳ期患者hnRNP A2/B1蛋白高表达者所占比例高于Ⅰ、Ⅱ期患者（P均<0. 05）。高 表达组无病生存患者比例低于低表达组，疾病复发和因结直肠癌死亡的患者比例高于低表达组（P均<0. 05）。在所 有患者、Ⅱ~Ⅲ期患者、Ⅱ期患者中，高表达组总生存时间和无病生存时间均短于低表达组（P均<0. 05）。Cox多因素 分析显示，hnRNP A2/B1 蛋白表达与 TNM 分期是结直肠癌患者总生存期和无病生存期的独立影响因素（P 均< 0. 05）。结论 结直肠癌组织中 hnRNP A2/B1 蛋白呈高表达，hnRNP A2/B1 蛋白高表达与结肠癌患者预后不良 有关。 [ABSTRACT FROM AUTHOR]

目的 观察玻璃体腔注射阿柏西普联合玻璃体切除术对增殖型糖尿病视网膜病变(PDR)的治疗效果。 方法 选取59例PDR患者并将其随机分为对照组29例, 观察组30例。两组行常规玻璃体切除术; 另外观察组于术 前3~5 d行玻璃体腔内注射阿柏西普0. 05 mL，按压注射部位30~60 s。用ELISA实验检测玻璃体腔内血管内皮生长 因子(VEGF)及促红细胞生成素(EPO); 采用光学相干断层成像(OCT)检测黄斑中心凹厚度(CMT)，采用ETDRS视 力表检查最佳矫正视力(BCVA)。同时统计术后1个月内两组医源性裂孔, 玻璃体积血, 前房积血及眼压升高等并 发症发生情况。结果 与对照组比较，观察组玻璃体腔内 VEGF, EPO 水平低(P 均<0. 05)。术后 1 周, 1 月，两组 CMT, BCVA低于术前，且观察组CMT, BCVA低于对照组(P均<0. 05)。观察组并发症发生率低于对照组(P<0. 05)。 结论 阿柏西普注射联合玻璃体切除术能够降低PDR患者玻璃体腔内VEGF, EPO水平，减轻黄斑水肿，提高术后 视力，降低手术并发症发生率. [ABSTRACT FROM AUTHOR]

甲状腺癌根据病理类型分为乳头状癌、滤泡状癌、髓样癌和未分化癌。乳头状癌和滤泡状癌又称分化型甲状腺癌,一般根治性手术切除后5年生存率90%以上。131I治疗是分化型甲状腺癌术后常用的辅助治疗措施,但部分患者病灶不摄碘或碘摄取不足,预后较差。除此之外,髓样癌和未分化癌对放射性碘治疗不敏感,预后亦较差。这类对放射性碘治疗效果不佳的甲状腺癌统称为碘难治性甲状腺癌。目前,碘难治性甲状腺癌主要采取靶向药物治疗。根据作用靶点不同,可将靶向药物分为酪氨酸激酶抑制剂（索拉非尼、乐伐替尼、凡德他尼、卡博替尼、帕唑帕尼、阿帕替尼）、BRAF抑制剂（维罗非尼、达拉非尼）以及MEK抑制剂（司美替尼）。其中,索拉非尼、乐伐替尼、凡德他尼、卡博替尼这4种靶向药物已被美国FDA批准上市,其他靶向药物,如维罗非尼、达拉非尼、帕唑帕尼等在临床试验中也取得较大突破。 [ABSTRACT FROM AUTHOR]

Copyright of Shandong Medical Journal is the property of Shandong Medical Health Newspapers and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Shandong Medical Journal is the property of Shandong Medical Health Newspapers and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Shandong Medical Journal is the property of Shandong Medical Health Newspapers and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Shandong Medical Journal is the property of Shandong Medical Health Newspapers and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

目的 观察子宫肌瘤细胞中孕激素受体M(PR-M)、孕激素受体A/B(PR-A/B)及porin蛋白的表达变 化,并探讨其意义。方法子宫肌瘤切除术中切取子宫肌瘤组织及瘤旁正常子宫平滑肌组织后冰上尽快送实验 室，原代培养子宫肌瘤细胞和正常子宫平滑肌细胞并鉴定。取第3代子宫肌瘤细胞（实验组）和正常平滑肌细胞 (对照组），采用Western blotting法检测细胞中的PR-M、PR-A、PR-B、porin蛋白，分析PR-M、PR-A、PR-B蛋白与por- in蛋白表达的相关性。结果实验组细胞中PR-M、PR-A、PR-B、Porin 蛋白相对表达量分别为0. 130 ±0.012、0.432 ±0.052、0.456 ±0.045、0.525 ±0.082,对照组分别为 0.086 ±0.015、0.223 ±0.036、0.269 ± 0.026、0. 202 土 0. 034,实验组细胞中PR-M、PR-A、PR-B蛋白和porin蛋白相对表达量均高于对照组（P 均 < 0.01)。实验组中 PR-M 蛋白与 porin 蛋白相对表达量呈正相关关系 0=0.464，P<0.05)。结论子宫肌瘤细胞中 PR-M、PR-A、PR-B、 porin 蛋白表达升高, PR-M、PR-A, PR-B, porin 蛋白表达异常可能与子宫肌瘤的发病有关,且 PR-M 蛋白与 porin 蛋 白可能在子宫肌瘤发病中起协同作用。 [ABSTRACT FROM AUTHOR]

Copyright of Shandong Medical Journal is the property of Shandong Medical Health Newspapers and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Shandong Medical Journal is the property of Shandong Medical Health Newspapers and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

目的 观察急性髓系白血病（AML）患者骨髓单个核细胞中Wilms基因（WT1）的表达，并分析其表达与疗效、预后的关系。方法 选择AML患者56例、非肿瘤患者28例。采用定量PCR法检测骨髓单个核细胞中WT1表达，并分析其表达与患者性别、年龄、外周血白细胞数量、骨髓原幼细胞比例、LDH水平的关系。首次诱导化疗后，观察不同WT1表达水平与AML患者的疗效、无事件生存（ EFS）时间、总生存（ OS）时间的关系。结果 AML患者WT1表达水平中位数为2875拷贝／10000 ABL拷贝，高表达阳性率为85．7％；非肿瘤患者WT1表达水平中位数为8拷贝／10000 ABL拷贝，无高表达患者。 WT1表达水平不同的AML患者性别、年龄、外周血白细胞数量、骨髓原幼细胞比例、LDH水平比较差异无统计学意义。 WT1表达正常AML患者首次诱导化疗后完全缓解率、中位EFS时间与WT1高表达AML患者比较，P均＞0．05。 WT1表达正常AML患者中位OS时间为29．5个月，WT1高表达AML患者为19个月，两者比较P均＜0．05。结论 AML患者WT1表达水平明显高于非肿瘤患者；AML患者WT1表达水平与患者的疗效、预后可能有关。 [ABSTRACT FROM AUTHOR]

Copyright of Shandong Medical Journal is the property of Shandong Medical Health Newspapers and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

目的　观察培门冬酶(ＰＥＧ-ＡＳＰ)联合ＣＨＯＰ方案化疗并序贯放疗治疗Ⅰ ∼Ⅱ期鼻腔ＮＫ/Ｔ细胞淋巴瘤 的疗效。方法　选择鼻腔ＮＫ/Ｔ细胞淋巴瘤患者114例，随机分为观察组和对照组各57例。两组均先行ＣＨＯＰ方 案化疗3个疗程，21ｄ为1个疗程；然后行受累野放疗，每周5次，持续5∼6周；继续行ＣＨＯＰ方案化疗3个疗程。 观察组每个化疗疗程的第1、12天肌内注射ＰＥＧ-ＡＳＰ，对照组每个化疗疗程的第1∼10天静脉滴注左旋门酰胺酶 (Ｌ-ＡＳＰ)。治疗后评价近期疗效，记录化疗不良反应；随访3年，评价生存情况及生存时间。结果　观察组总有效 率为94.7%，高于对照组的78.9%(Ｐ<0.05)。化疗期间，观察组过敏反应、胃肠道反应及转氨酶升高等发生率均 低于对照组(Ｐ均<0.05)。观察组1、3年生存率分别为100%、93.0%，生存时间(27.4±5.2)个月；对照组分别为 86.0%、75.4%、(20.7±6.8)个月；两组比较，Ｐ均<0.05。结论　ＰＥＧ-ＡＳＰ联合ＣＨＯＰ方案化疗并序贯放疗治疗 Ⅰ ∼Ⅱ期鼻腔ＮＫ/Ｔ细胞淋巴瘤安全有效。 [ABSTRACT FROM AUTHOR]